Evidence that Amphotericin B Mediates Reactivation of Latent Epstein-Barr Virus in Hodgkin's Lymphoma Allowing Cytotoxicity by Acyclovir
Yonsei Medical Journal
;
: 287-290, 2006.
Article
Dans Anglais
| WPRIM
| ID: wpr-51463
ABSTRACT
This brief communication focuses on aspects of a recent case report (Yonsei Med J 2005;46425-30) on a full and sustained remission of Hodgkin's lymphoma (HL) after a single day of chemotherapy. A septic episode required stopping chemotherapy and starting amphotericin B and acyclovir. Remission evidence was seen within days of starting these. A review of research supporting the notion that amphotericin B can reactivate latent Epstein-Barr virus and thus allow acyclovir to kill infected HL cells is given. Experimental work is required to confirm or refute this possibility. If successful, amphotericin B and acyclovir treatment could be extended to other EBV-driven cancers such as Burkitt's lymphoma, nasopharyngeal carcinoma and the occasional EBV-related epithelial cancer of the breast, colon, prostate, and others.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Activation virale
/
Induction de rémission
/
Aciclovir
/
Maladie de Hodgkin
/
Ganciclovir
/
Amphotéricine B
/
Lymphome de Burkitt
/
Facteur de nécrose tumorale alpha
/
Herpèsvirus humain de type 4
/
Synergie des médicaments
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Yonsei Medical Journal
Année:
2006
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS